Page 5,006«..1020..5,0055,0065,0075,008..5,0205,030..»

Autism Treatment Service Agency, Working With Autism’s Board Certified Behavior Analyst (BCBA) Credentialed Staff

Posted: Published on August 1st, 2013

uding Santa Clarita, Saugus, Canyon Country, Valencia and Newhall) (PRWEB) August 01, 2013 Los Angeles County, Santa Clarita, CA (incl Working With Autism Incs. (WWA) team of professionals now includes two additional BCBA staff members, making it one of few full service autism agencies offering standardized ABA services for children, teens and young adults. Under the tutelage of John-Paul Prakash, WWA BCBA Program Services Director, Amanda Hsu and Yuki Sumitomo are now the most recent staff members to attain the BCBA distinguished credential. Coming to fruition in the early 90s, BCBA credentials are now internationally recognized, serving as an attempt to set standards for qualified behavior analyst practicum. Children and families serviced by experienced BCBA professionals, can expect carefully constructed, individualized and detailed behavior analytic treatment plans, a clear understanding of the current function of behaviors demonstrated, and treatment protocols that are implemented repeatedly and consistently for continued program success. Parents of children or teens with autism may take advantage of the financial support allotted by collaborating with a BCBA certified supervisor. Specifically, most large insurance corporations, including the US Military Health Insurance, pay for ABA services for individuals with autism if they are delivered by a practitioner certified by … Continue reading →

Comments Off on Autism Treatment Service Agency, Working With Autism’s Board Certified Behavior Analyst (BCBA) Credentialed Staff

Ambulance trust stroke response ‘unacceptable’, says MP

Posted: Published on August 1st, 2013

East of England Ambulance Trust ambulances work out out of the Norwich office in Hellesdon. PHOTO BY SIMON FINLAY Adam Gretton Health correspondent adam.gretton@archant.co.uk Thursday, August 1, 2013 6:30 AM A MP said response times to stroke patients in Norfolk and Suffolk were still totally unacceptable, despite the regions ambulance service hitting its target for the first time in 14 months. To send a link to this page to a friend, you must be logged in. The East of England Ambulance Service is meant to get at least 56pc of patients suffering from a suspected stroke to a hospital within 60 minutes. Board members of the NHS trust yesterday welcomed the news that 58.8pc of stroke patients across the six counties it serves received thrombolysis treatment at an acute stroke centre within 60 minutes of making a 999 call during the month of May. However, in the first quarter of 2013/14, the ambulance services stroke 60 performance was 51.8pc and a breakdown of the figures for Norfolk and Suffolk show that only 43.5pc of patients were taken to a hospital within the hour target. Norman Lamb, MP for North Norfolk and health minister, yesterday said improving responses to stroke patients … Continue reading →

Comments Off on Ambulance trust stroke response ‘unacceptable’, says MP

Trial Results Prove Potential Benefit From Treating Select Stroke Patients With Minimally Invasive Therapy

Posted: Published on August 1st, 2013

Home Mail News Sports Finance Weather Games Groups Answers Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo! Home Video Photos GMA Year in Review LiveRoom Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials The Lookout Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Lookout The Sideshow Around the World Katie's Take Power Players This Could Be Big Newsmakers Trending Now Just … Continue reading →

Comments Off on Trial Results Prove Potential Benefit From Treating Select Stroke Patients With Minimally Invasive Therapy

Cerevast Therapeutics Initiates Phase 3 Clotbust ER™ Clinical Study for the Treatment of Acute Ischemic Stroke

Posted: Published on August 1st, 2013

REDMOND, Wash., Aug. 1, 2013 /PRNewswire/ -- Cerevast Therapeutics, Inc., a privately-held medical technology company, announced today that it has initiated patient enrollment in its Phase 3 clinical trial evaluating the use of the Company's proprietary Clotbust ERTM ultrasonic headframe for the treatment of acute ischemic stroke. This worldwide study intends to enroll up to 800 ischemic stroke patients in a randomized, double-blinded clinical trial designed to evaluate the efficacy and safety of the Clotbust ERTM ultrasound device when used in combination with standard intravenous thrombolytic therapy (tissue plasminogen activator - tPA/Alteplase). (Logo: http://photos.prnewswire.com/prnh/20111219/SF24705LOGO) Clotbust ERTM is a first-in-class ultrasound device for the treatment of ischemic stroke, representing a novel product with the potential to serve as the most significant advancement in stroke care since tPA was approved in 1996. Designed for rapid deployment in the emergency room setting, the device has been engineered to non-invasively deliver therapeutic ultrasound energy to the region of the occluded vessel in the brain. Clinical data from five independent studies has demonstrated that combining the acoustic energy of ultrasound with conventional intravenous (IV) tPA therapy dissolves blood clots more completely and provides patients with better long term clinical outcomes compared to IV tPA therapy … Continue reading →

Comments Off on Cerevast Therapeutics Initiates Phase 3 Clotbust ER™ Clinical Study for the Treatment of Acute Ischemic Stroke

Dr. Joanne Kurtzberg comments: Girl writes for first time after cord blood infusion

Posted: Published on August 1st, 2013

Complications during an oral surgery injured Grace Rosewood's brain so much so that when she celebrated her second birthday, the young girl could barely walk or even lift her head. "She was diagnosed with hypotonic cerebral palsy, so shes weak all over her body, but its not from the muscles, its from the brain," OIivia Rosewood said. "She had difficulty picking things up. She couldnt hold a pencil, and it was not just the coordination, it was the strength." So when Olivia heard about a cutting edge procedure being pioneered at Duke University using infusions of umbilical cord blood, she signed Grace up. Dr. Joanne Kurtzberg, a researcher at Duke University who was conducting a clinical trial, said the cells in cord blood may have the ability to repair damage in the body. "We are taking cord blood that parents have banked when children were born, thawing them out and washing them, and infusing them directly into the childs blood," she said. "The cells are smarter than we are. And they are attracted to areas of injuries by signals given off by the cells inside the childs body that are near the injury." Grace received three infusions of her own … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on Dr. Joanne Kurtzberg comments: Girl writes for first time after cord blood infusion

Autism: 'different developmental brain chemistry'

Posted: Published on August 1st, 2013

Featured Article Academic Journal Main Category: Autism Also Included In: Neurology / Neuroscience Article Date: 01 Aug 2013 - 4:00 PDT Current ratings for: Autism: 'different developmental brain chemistry' Researchers have discovered that children with autism can be set apart from those with other developmental disorders through differences in chemical changes in the brain. The study, published in JAMA Psychiatry, reveals that gray matter chemical changes that occur between the ages of 3 and 10 years differentiate children with autism spectrum disorder from those with idiopathic (an unknown cause) developmental disorder. Researchers from the University of Washington, Seattle, analyzed three groups of children in different age groups: one group at age 3 to 4 years, one at 6 to 7 years and one at 9 to 10 years. All groups had a mix of children with autism spectrum disorder, developmental disorder and "typical development." The participants with autism spectrum disorder and idiopathic developmental disorder were analyzed using data from proton magnetic resonance imaging (MRI), while those with typical development were assessed using cross-sectional data. Between 3 and 10 years of age there were specific differences in rates of change in the brain chemicals cerebral gray matter N-acetylaspartate, choline and creatine. … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Autism: 'different developmental brain chemistry'

Late Summer Hikes can Lead to Harmful Animal Bites, Reminds J. Shaffer Smith

Posted: Published on August 1st, 2013

LOS ANGELES, Aug. 1, 2013 /PRNewswire/ --J. Shaffer Smith & Associates is dedicated to assisting those who need help the most. That's why, for the ideal Los Angeles brain injury lawyer, J. Shaffer Smith is always the optimal choice. For years, Mr. Smith has garnered a reputation as the personal injury and construction accident attorney Los Angeles trusts to win ample settlements over $ billion to date! Not surprisingly, in the late summer, when many people find themselves enjoying the outdoors, an unusually high number of those in need of a first-class attorney are dog bite victims. Thus, it's always a great relief to learn that the team at J. Shaffer Smith & Associates includes the dog bite attorneys Los Angeles can rely on. Almost one half of all dog bites involve an animal owned by the victim's family or neighbors, and research shows that a large percentage of dog bite victims are young children. In fact, approximately 4 million Americans are bit by dogs every year, and around 800,000 of these victims seek medical treatment. Expert attorney, J. Shaffer Smith, points out that no matter how friendly and lovable a dog may be it might attack when threatened. Further … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Late Summer Hikes can Lead to Harmful Animal Bites, Reminds J. Shaffer Smith

Neuralstem Cells Reverse Cognitive Defect In Brain-Irradiated Rats, University Of California Irvine Paper Shows

Posted: Published on August 1st, 2013

ROCKVILLE, Md., Aug. 1, 2013 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced that a paper published in the journal "Cell Transplantation - The Regenerative Medicine Journal," reported that Neuralstem's spinal cord-derived human neural stem cells, NSI-566, improved cognitive function in rats who'd received radiation to the brain, as assessed by two separate cognitive tasks (http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct1048acharya ). In the paper, "Transplantation of Human Fetal-Derived Neural Stem Cells Improves Cognitive Function Following Cranial Irradiation," researchers at the University of California Irvine showed that rats who received NSI-566 transplants after brain irradiation improved hippocampal spatial memory as well as contextual fear conditioning performance, a brain function that relies on intact amygdala function. Both the amygdala and the hippocampus are parts of the brain involved with memory formation. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) The transplanted cells developed into a significant number of new neurons in the hippocampus, as well as a smaller portion of glial subtypes. There was no evidence of teratoma, or tumor growth, in these cells. Radiation after tumor-removal surgery is a common therapy in the treatment of brain cancer in humans, but can result in significant cognitive defects. "We are broadening our neural stem cell therapy programs from treating motor deficits to treating … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Neuralstem Cells Reverse Cognitive Defect In Brain-Irradiated Rats, University Of California Irvine Paper Shows

US Army Selects Premier Biomedical, Inc. for Cure for Traumatic Brain Injury, Clinical Depression, and Suicide …

Posted: Published on August 1st, 2013

El Paso, TX, August 1, 2013 Premier Biomedical, Inc. (BIEI) On July 10, 2013, Premier Biomedical, Inc. and the US Army hosted a joint press conference in El Paso, Texas to announce their new partnership and a potential breakthrough cure for traumatic brain injury and suicidal ideation. Army Lieutenant Colonel Shawna Scully, chief neurologist of the William Beaumont Army Medical Center, and Premier Biomedical, Inc.s CEO William A. Hartman spoke at the announcement ceremony. Army Lt. Col. Dr. Shawna Scully, chief neurologist at WBAMC, commented on the history of traumatic brain injury and suicidal ideation and the alarming prevalence of these cases among active duty military and veterans. Scully noted that initial laboratory testing indicates that Premier Biomedicals technology may be effective in removing the molecules that cause such neurological problems for soldiers with brain injuries. Scully also commented on the separate but recent achievement by Premier Biomedical, Inc. and the University of Texas at El Paso in developing a drug therapy for mice with breast cancer that greatly outperformed chemotherapy in its early trials. Highlights of the Joint Conference can be found at http://www.youtube.com/watch?v=pvXUphEbEuM. Full length videos of the conference and of individual speakers can be found on the … Continue reading →

Posted in Brain Injury Treatment | Comments Off on US Army Selects Premier Biomedical, Inc. for Cure for Traumatic Brain Injury, Clinical Depression, and Suicide …

Out With the Old, In With the New in Treating MS

Posted: Published on August 1st, 2013

By Ryan Guenette - July 31, 2013 | Tickers: BIIB, NVS, PFE, SNY, TEVA | 0 Comments Ryan is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited. Hidden beneath all the numbers and metrics in Biogen Idec's(NASDAQ: BIIB) recent earnings reportis a key confirmation of a shifting market in the treatment of multiple sclerosis. This alteration could yield billions of dollars for companies positioned to take advantage of it. What Happened On July 25, Biogen reported second-quarter financial results. Earnings of $2.30 per share and revenue of $1.7 billion both trumped estimates, while the company's higher guidance fueled investors'optimism regarding the company's future.However, neither development could steal the report's spotlight away from the unexpected success of the companys new multiple sclerosis oral drug, Tecfidera. The drug generated sales of $192 million in the quarter, more than double what the Street expected. A Coming Revolution in MS Treatment Contrary to most current multiple sclerosistreatments , Tecfidera is a pill, not an injection. The treatments which currently dominate this $14.4 billion global market-- Avonex (Biogen), Copaxone (Teva), Tysabri (Biogen), Rebif (Pfizer & EMD Sereno) -- are all injections. … Continue reading →

Posted in MS Treatment | Comments Off on Out With the Old, In With the New in Treating MS

Page 5,006«..1020..5,0055,0065,0075,008..5,0205,030..»